Scope
NICE NG250 integrates assessment and management of community- and hospital-acquired pneumonia in adults and children. Its updated recommendations include selective microbiology, shorter courses for narrowly defined childhood disease, corticosteroids for severe adult community-acquired pneumonia and targeted follow-up imaging. This selected summary emphasizes clinical stability, local resistance and safe escalation rather than treating a mortality score as a complete care decision.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Combine severity scores with clinical assessment
- In adult community-acquired pneumonia, use CRB65 in primary care with clinical judgement. Consider hospital referral at a score of 2 or more; a score of 1 allows individualized community, same-day, hospital-at-home or inpatient care. A score of 0 usually supports primary care with safety-netting. [1]
- For adults assessed in hospital with community-acquired pneumonia, combine CURB65 with clinical judgement: consider inpatient care at 3 or more, with critical care when appropriate; at 2, consider monitored alternatives or admission; at 0–1, consider discharge with primary-care follow-up and safety-netting. [1]
- Refer adults with cardiorespiratory failure, sepsis or another serious condition to hospital regardless of the score. For children, consider hospital referral or specialist paediatric advice. Home-care decisions must also account for frailty, comorbidity, treatment plans, home safety and support. [1]
Use imaging and microbiology for the clinical question
- In adults presenting to hospital with suspected community-acquired pneumonia, organize diagnosis including chest X-ray within 4 hours. Lung ultrasound can support rapid assessment, alternative diagnoses such as heart failure or pleural complications; consider baseline CRP on adult admission. [1]
- Do not routinely send microbiology for low-severity adult or non-severe paediatric community-acquired pneumonia. In moderate- or high-severity adults, consider blood cultures when additionally indicated, sputum cultures based on context and sample quality, pneumococcal urinary antigen to narrow therapy and legionella antigen when risk factors exist. [1]
- For severe community-acquired pneumonia in children, consider blood cultures with additional indications such as sepsis and age-appropriate sputum sampling; do not routinely use urinary antigens. For hospital-acquired pneumonia, send an appropriate respiratory sample for microbiology. [1]
Start promptly and choose treatment using local resistance
- Start antibiotics promptly once community-acquired pneumonia is diagnosed, within 4 hours of hospital presentation. For hospital-acquired pneumonia, start within 4 hours of clinical suspicion in hospital or presentation from outside. Suspected sepsis follows its separate antibiotic-timing pathway. [1]
- Use oral antibiotics when feasible and severity permits. Review intravenous treatment by 48 hours and switch to oral treatment when appropriate. Review microbiology when available and consider narrowing treatment according to results. [1]
- Choose community-acquired pneumonia therapy by clinical severity, relevant comorbidity, local resistance and infection surveillance, prior antibiotics and microbiology, including resistant-organism colonisation. Adult scores support assessment; paediatric severity depends on clinical judgement. [1]
- For low-severity adult community-acquired pneumonia, NICE’s first oral choice is amoxicillin 500 mg three times daily for 5 days, with higher doses possible under prescribing guidance. Moderate disease uses amoxicillin and adds a macrolide if atypical pathogens are suspected; severe disease has a separate combination regimen. [1]
Use short courses only within their eligibility and stability limits
- For adults with community-acquired pneumonia, stop after 5 days unless microbiology requires longer treatment or clinical instability remains. Instability includes fever in the previous 48 hours or more than one of: systolic pressure below 90 mmHg, pulse above 100/minute, respiratory rate above 24/minute, or oxygen saturation below 90% on room air (or failure to meet long-term baseline oxygen requirements). [1]
- Offer 3 days of antibiotics only for children aged 3 months corrected gestational age through 11 years with non-severe community-acquired pneumonia and no complications or underlying disease. Consider extension if unstable. For other paediatric community-acquired pneumonia, stop at 5 days unless microbiology or instability requires longer. [1]
Distinguish onset, resistance risk and review
- Pneumonia beginning within 48 hours of admission follows the community-acquired pathway. For onset on days 3–5, consider that pathway only without higher resistance risk; severe lung disease, immunosuppression, recent broad-spectrum antibiotics, resistant colonisation or prior healthcare contact change that assessment. [1]
- For hospital-acquired pneumonia, use ward-level resistance, onset timing, previous treatment, cultures and complication risk to choose therapy. Review after 5 total days and consider stopping if stable. Seek microbiology advice for poor response or multidrug-resistant organisms. [1]
Use steroids and respiratory support selectively
- In hospitalized adults with high-severity community-acquired pneumonia, consider corticosteroids alongside antibiotics for 4–7 days or until earlier discharge. Consider intravenous hydrocortisone first, or another appropriate corticosteroid if unsuitable. Avoid coadministration with a fluoroquinolone under the cited safety advice. [1]
- For respiratory failure with inadequate saturation on standard oxygen, consider a high-flow nasal oxygen trial using multidisciplinary assessment, clinical trajectory, tolerance and preferences. Choose a setting that can address failure and possible invasive ventilation, consistent with the escalation plan. [1]
Reassess treatment failure and plan safe follow-up
- Reassess pneumonia that worsens or fails to improve as expected. Community-acquired pneumonia not responding to antibiotics warrants hospital referral, consideration of non-bacterial causes and microbiological sampling if not already obtained. [1]
- In hospital, consider CRP or procalcitonin at day 3 or 4 when treatment failure is clinically suspected. High or insufficiently improving values may prompt senior review. [1]
- Do not routinely discharge an adult with community-acquired pneumonia if at least 2 instability findings occurred in the preceding 24 hours: temperature above 37.5°C, respiratory rate at least 24/minute, pulse above 100/minute, systolic pressure at most 90 mmHg, oxygen saturation below 90% on room air or failure to meet long-term baseline oxygen requirements, abnormal mentation or inability to eat independently. [1]
- Explain antibiotic adverse effects and seek review for rapid worsening, systemic illness or no initial improvement within 3 days. In children, persistent fever with increased breathing effort, reduced drinking or feeding, or unresolved fatigue needs further advice; an improving cough alone may last up to 4 weeks. [1]
- Do not routinely arrange a follow-up chest X-ray after inpatient pneumonia. Consider one at 6 weeks for underlying-disease or cancer risk, persistent or worsening symptoms, or unexplained weight loss, using shared decision making informed by prior imaging, frailty, prognosis and preferences. [1]
Limitations and use
- The full antibiotic tables, paediatric doses, allergy alternatives, resistant-pathogen regimens and organ-impairment adjustments are not reproduced. UK preferred regimens require current Indian resistance and product-applicability assessment.
- This summary does not cover ventilator-associated pneumonia, a full sepsis protocol or a fixed respiratory-support escalation algorithm. Adult severity scores must not be extrapolated to children or override severe clinical findings.
- Short-course eligibility and stability criteria are distinct from discharge criteria. The summary does not supply a corticosteroid dose, universal oxygen target or biomarker-only treatment decision.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Pneumonia: diagnosis and management
Selected recommendation material consulted
Publication details
- Issuing organisation
- NICE
- First published
- 2 September 2025
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.